Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences announced the publication of peer-reviewed expert recommendations guiding glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated with CRENESSITY. Published in The Journal of Clinical Endocrinology & Metabolism, the algorithms provide clinicians with systematic approaches to reduce supraphysiologic glucocorticoid doses in both pediatric and adult populations.
Key figures
- Adult patients
- 182
- Pediatric patients
- 103
- Trial patient count
- 285
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.